GRACE: diagnostics' role in EU AB resistance
This article was originally published in Clinica
Executive Summary
The involvement of small and medium-sized companies that can help to develop bedside diagnostic tests is seen as vital in the context of a scientific network that has just been launched by the European Commission. The network's overall aim is to tackle increasing resistance to antibiotics (AB) through genomics. Entitled GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired lower respiratory tract infections in Europe), the network brings together 17 academic groups from nine EU member states.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.